Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00412321 · ClinicalTrials.gov registry record · Phase 1
A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
A Phase 1 study, sponsored by Centocor.
- Completed
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT00412321 is a Phase 1 study that has completed, run by Centocor. The registered enrollment target is 67 participants.
The verdict
NCT00412321, a Phase 1 study, has completed, sponsored by Centocor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate of the study of different CNTO 328 doses and schedules and to see if CNTO 328 has any effect on Non-hodgkin's Lymphoma, Multiple Myeloma or Castleman's disease.
Interventions
- DRUG CNTO 328
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2005-05 |
| Est. Completion | 2011-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00412321
The ClinicalTrials.gov registry entry for NCT00412321 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centocor, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CNTO 328 is the first listed.
NCT00412321 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00412321 about?
NCT00412321 is a clinical study titled "A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease". The purpose of this study is to evaluate of the study of different CNTO 328 doses and schedules and to see if CNTO 328 has any effect on Non-hodgkin's Lymphoma, Multiple Myeloma or Castleman's disease.
What is the current status of trial NCT00412321?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2005-05. Estimated completion is 2011-04.
What interventions are being tested in trial NCT00412321?
The interventions under investigation include: CNTO 328 (DRUG).
Who is sponsoring clinical trial NCT00412321?
This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.